Back

Hybrid ablation versus repeated catheter ablation in persistent atrial fibrillation: long-term results of the HARTCAP-AF trial.

8 April 2024 (10:30 - 11:15)
Organised by: Logo
Congress Presentation Part of: Atrial fibrillation: treatment 2 Rhythm Control, Hybrid Therapy EHRA Premium Access EHRA 2024 European Heart Rhythm Association (EHRA)

About the speaker

Photo
Ms Claudia van der Heijden

Maastricht University Medical Centre (MUMC), Maastricht (Netherlands (The))

8 More presentations in this session

Presentation thumbnail
Long-term outcomes in hybrid versus standalone thoracoscopic ablation in patients with atrial fibrillation: a systematic review and reconstructed individual patient data meta-analysis.
Miss L. Aerts (Maastricht, NL)
Abstract Slides Video
Presentation thumbnail
Intra-procedural three-dimensional rotational angiography in cryoballoon ablation of atrial fibrillation - results from a randomised clinical trial
Doctor I. Prepolec (Zagreb, HR)
Abstract Slides Video
Presentation thumbnail
The hybrid ablation approach to treating long-standing persistent atrial fibrillation: real-world data from a tertiary institution
Doctor V. Lim (Coventry, GB)
Abstract Slides Video
Presentation thumbnail
LINAC-Based STereotactic Arrhythmia Radioablation (STAR) for paroxysmal atrial fibrillation in elderly: a prospective phase II trial
Doctor I. Romanazzi (Bari, IT)
Abstract Slides Video
Presentation thumbnail
Two-year safety and effectiveness of hybrid ablation versus catheter ablation in patients with non-paroxysmal AF: mid-term results of the CEASE-AF trial
Doctor M. Wijffels (Nieuwegein, NL)
Abstract Slides Video

Access the full session

Session thumbnail
Atrial fibrillation: treatment 2

The Event

Event poster

EHRA 2024

8 April 2024 10:30 CET
You may be interested in
thumbnail
Congress Presentation
Hybrid ablation approach for long-standing persistent atrial fibrillation
thumbnail
Congress Presentation
Hybrid AF ablation: EP meets the surgeon
thumbnail
Congress Presentation
The hybrid ablation approach to treating long-standing persistent atrial fibrillation: real-world data from a tertiary institution

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources